对个体患者数据的元分析估计了老年抑郁量表-15的最小可检测变化
Nadia P González-Domínguez1, Yin Wu2, Suiqiong Fan2
1Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada.
Journal of clinical epidemiology
|June 28, 2024
概括
老年抑郁量表-15 (GDS-15) 的最小可检测变化 (MDC) 为3.81分 (MDC95). 这种MDC随着参与者中患有重度抑郁症比例较高而增加,有助于评估症状变化.
科学领域:
- 老年精神病学是一门精神病学专业.
- 心理测量验证 心理测量验证
- 临床流行病学临床流行病学
背景情况:
- 老年抑郁症尺度-15 (GDS-15) 是一种广泛使用的老年人抑郁症查工具.
- 了解最小可检测变化 (MDC) 对于解释个体得分波动至关重要.
- 之前对GDS-15MDC的估计缺乏跨不同种群和研究的全面分析.
研究的目的:
- 用个人参与者数据元分析 (IPDMA) 来估计老年抑郁症尺度-15 (GDS-15) 的最小可检测变化 (MDC).
- 调查MDC是否根据参与者特征 (年龄,性别) 和研究水平因素 (平均年龄,抑郁症患病率,招聘环境) 变化.
主要方法:
- 对现有IPDMA数据集的二次分析,重点关注GDS抑郁查准确度.
- 包括60岁及以上参与者GDS-15分数的研究.
- 通过随机效应元分析估计MDC95 (3.81分) 和MDC67 (1.95分).
- 亚组分析和元回归来探索MDC根据参与者和研究特征的变化.
主要成果:
- 分析包括来自21项研究的5876名参与者 (平均年龄76岁,40%是男性,11%患有严重抑郁症).
- MDC95为3.81 (95%CI为3.594.04) 和MDC67为1.95 (95%CI为1.832.03) 的情况.
- MDC95随着年龄的增长而略有增加,并且与较高比例的参与者患有严重抑郁症有显著的关联,但与性别或招聘环境无关.
结论:
- 已建立的MDC95 (3.81) 和MDC67 (1.95) 为GDS-15.5提供了基准.
- 发现MDC95随着抑郁症患病率的增加而增加,这对于临床解释很重要.
- 这些估计对于评估抑郁症症状的个体变化和为最小临床重要差异评估提供信息是有价值的.
相关概念视频
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...